Barmania, Fatima; Pepper, Michael S. C-C chemokine receptor type Five (CCR5): An emerging target for the control of HIV infection. Applied & Translational Genomics, Pretoria, v. 2, n. 2, p.3-16, maio 2013.

Barré-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W. and L. Montagnier. (1983). Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS). Science.220:868-871

Brooks, G. F.; Butel, J. S.; Morse, S. A.; , 21^th ed., Guanabara Koogan: Rio de Janeiro, 2000.

Buonaguro, L., M. Tagliamonte, M. L. Tornesello, and F. M. Buonaguro.(2007). Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology 4:34.

Castagna, A. et al. Dolutegravir in antirretroviral-experienced patients with raltegravir and/or elvitegravir-resistant HIV-1: 24 week results of the phase III VIKING-3 study. Journal of infectious diseases 2013 (2014): 354-362.

Cahn et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, doublé-blind, non inferiority SAILING study. Lancet 2013; 382: 700-08.

Cann, A.J., Principles of Molecular Virology, ed. Elsevier. Vol. 4ª ed. 2005, Oxford.

Canki, M; Lee, D. Methods, compositions for the use of Sargassum fusiforme for the inhibition of HIV-1 infection. U.S. patent. (2007); 60(931):619.

Clavel, F.; Guetard, D.; Brun-Vezinet, F.; Chamaret, S.; Rey, M.A.; Santos-Ferreira, M.O.; Laurent, A.G.; Dauguet, C.; Katlama, C.; Rouzioux, C. et al. (1986). Isolation of a new human retrovirus from West African patients with AIDS. Science 233: 343–346.

Coffin,J.; Haase, A.;Levy,J.A.;Montagnier,L.;Oroszlan,S.;Teich,N.What to call the AIDS vírus? Nature,Vol.10. 1986.

Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; D.H. Crawford, M.F. Greaves, R.A. Weiss.The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovírus. Nature, 312 (1984), pp. 763-767.

De Cock, K. M., H. W. Jaffe, and J. W. Curran.(2011). Reflections on 30 years of AIDS. Emerg. Infect. Dis. 17:1044-1048.

Dean, M.; Carrington, M.; Winkler, C.; Huttley, G.A.; Smith, M.W.; Allikmets, R.; Goedert, J.J.; Buchbinder, S.P; Vittinghoff, E.; Gomperts, E.; Donfield, S.; Vlahov, D.; Kaslow, R.; Saah, A.; Rinaldo, C; Detels, R. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 273 (1996), pp. 1856-1862

Deng, H.; R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper, T.J. Schall, D.R. Littman, N.R. Landau. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 381 (1996), pp. 661-666.

Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Mccartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005.Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother. 49:4721-4732.

Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart.1995.Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.

Feinberg, J.; Clotet, B.; KHUONG, M.A. Once-daily dolutegravir (DTG) is superior to duranavir/ritonavir (DRV/r) in antiretroviral naive adults: 48 weeks results from FLAMINGO (ING 114915) [abstract H-1464]. In 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013.

Gao, F., N. Vidal, Y. Li, S. A. Trask, Y. Chen, L. G. Kostrikis, D. D. Ho, J. Kim, M.D.Oh, K. Choe, M. Salminen, D. L. Robertson, G. M. Shaw, B. H. Hahn, and M. Peeters. 2001. Evidence of Two Distinct Subsubtypes within the HIV-1 Subtype A Radiation. AIDS Res.Hum. Retroviruses.17: 675-688.

Gallo, R. C., P. S. Sarin, E. P. Gelmann, M. Robert-Guroff, E. Richardson, V. S. Kalyanaraman, D. Mann, G. D. Sidhu, R. E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic. 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865-867.

Gómara, M.J.; Pérez, Y.; Yuste, E.; Gómez-Gutierrez, P.; Pérez, J.J.; Haro, I. Structural study of a new hiv-1 entry inhibitor and interaction with the HIV-1 fusion peptide in dodecylphosphocholine micelles. Chemistry, 2017, Aug 25; 23(48):11703-11713.

Göttlinger, H.G. HIV-1 Gag: a Molecular Machine Driving Viral Particle Assembly and Release. In: HIV Sequence Compendium, F.B. Kuiken C, Hahn B, Marx P, Fang X, Li X, Stanton B, Hong Y, Zhang L, Zhao G, Lin D. Parental HIV/AIDS and psychosocial adjustment among rural Chinese children. J Pediatr Psychol. 2009;34(10):1053–1062.

Grotto, Rejane M.T.; PARDINI, Maria I.M.C. Biologia molecular do HIV-1 e genética da resistência humana à AIDS. Arq Ciênc Saúde, Botucatu, v. 13, n. 3, p.61-64, jul. 2006.

Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000.Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells. Science. 287:646-650.

Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13-W23.

Hughes, P.J.; Cretton-Scott, E.; Teague, A.; Wensel, T.M.; Proetease inhibitors for patients with HIV-1 infection: A comparative overview. Pharmacy and Therapeutics. 2011; 36(6):332-345.

Janssens, W., L. Heyndrickx, K. Fransen, J. Motte, M. Peeters, J. N. Nkengasong, P. M. Ndumbe, E. Delaporte, J. L. Perret, C. Atende, P. Piot, and G. van der Groen. 1994. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. AIDS Res. Hum. Retrovir. 10:877-879.

Kilgore, N. R., K. Salzwedel, M. Reddick, G. P. Allaway, and C. T. Wild.2003. Direct Evidence that C-Peptide Inhibitors of Human Immunodeficiency Virus Type 1 Entry Bind to the gp41 N-Helical Domain in Receptor-Activated Viral Envelope.J. Virol. 77:7669-7672.

Kwong, P.D.; Wyatt, R.; Robinson, J.; Sweet, R.W.; Sodroski, J.; Hendrickson, W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686):648-59, Jul,1998.

Kostrikis, L. G., E. Bagdades, Y. Cao, L. Zhang, D. Dimitriou, and D. D. Ho. 1995. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J. Virol. 69:6122-6130.

Votteler, Human Immunodeficiency Viruses: Molecular Biology, in Desk Encyclopedia of General Virology, A. Press, Editor. 2008: San Diego.

Larder, B.R., D.; Vella, S., HIV Resistance and Implications for Therapy, ed. M. Inc. Vol. 2ª ed. 2001, Atlanta.

Leitner, T., A. Alaeus, S. Marquina, E. Lilja, K. Lidman, and J. Albert. 1995. Yet another subtype of HIV type 1? AIDS Res. Hum. Retrovir. 11:995-997.

Levy, J.A., Pathogenesis of human immunodeficiency virus infection. Microbiol Rev, 1993. 57(1): p. 183-289.

Lindwasser, O.W; Resh, M.D. Myristoylation as a target for inhibiting HIV assembly: Unsaturated fatty acids block viral budding. Proc Natl Acad Sci USA. 2002;99(20):13037–13042.

Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. A. Eddy, G. van der Groen, K. Fransen, G. M. Gershy-Damet, R. De Leys, and D. S. Burke. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 7:769-780.

Madruga, J.V.; Berger, D.; McMurchie, M. et al. Efficacy and safety of duranavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experience, HIV infected patients in TITAN: a randomised controlled phase III trial. Lancet, 2007, Jul 7;370 (9581): 49-58.

McCutchan, F. E. 2006. Global epidemiology of HIV. J. Med. Virol. 78(Suppl. 1):S7-S12.

Merluzzi, V. J.,K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, and J. Adams. 1990.Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1411-1413.

Mitsuya, H., and S. Broder.1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 83: 1911-1915.

Moller, B.K. Andresen, B.S.; Christensen, E.I.; Petersen, C.M. Surface membrane CD4 turnover in phorbol ester stimulated T-lymphocytes. Evidence of degradation and increased synthesis. FEBS Lett. 1990; 276(1–2):59–62.

Molotkovsky, R.J. et al.(2018).Lateral Membrane Heterogeneity Regulates Viral-Induced Membrane Fusion during HIV Entry. May 16; 19(5). pii: E1483. doi: 10.3390/ijms19051483.

Moore, J. P., and J. Sodroski. 1996. Antibody Cross-Competition Analysis of the Human Immunodeficiency Virus Type 1 gp120 Exterior Envelope Glycoprotein. J. Virol. 70:1863-1872.

Moltó, J. et al. Reduced duranavir dose is a effective in maintaining HIV supression as the standard dose in virologically supressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother. 2015 Apr;70(4): 1139-45.

Murphy, K. Imunobiologia de Janeway. 8.ed. Porto Alegre: Artmed, 2014.

Myers, G., K. MacInnes, and B. Korber. (1992). The emergence of simian/human immunodeficiency viruses. AIDS Res. Hum. Retrovir. 8:373-386.

Osmanov, S., C. Pattou, N. Walker, B. Schwardlander, J. Esparza, et al. (2002). Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 29:184-190.

Paskaleva, E.E.; Lin, X.; Li, W. et al. Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme. AIDS Res Ther. 2006;3(1):15.

Paskaleva, E.E.; Lin, X.; Duus, K. et al. Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase. Virol J. 2008;5(1):8.

Paskaleva, E.E. et al. Palmitic acid is a novel CD4 fusion inhibitor that block HIV entry and infection. (2009). Dec, 25 (12): 1231-1241.

Peeters, M. (2001). Recombinant HIV sequences: their role in the global epidemic, p. 54-72. In C. Kuiken, B. Foley, B. Hahn, F. E. McCutchan, J. W. Mellors, J. I. Mullins, J. Sodroski, S. Wolinsky, and B. Korber (ed.), HIV sequence compendium 2000. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.

Popovic, M.; Sarngadharan, M.G.; Read, E.; Gallo, R.C. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 497–500.

Raffi, F.; Jaeger, H.; Quiros-Roldan, E. et al. Once daily dolutegravir versus twice-daily raltegravir in antirretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, non-inferiority trial. Lancet Infect Dis 2013; 13:927-35.

Requejo, H.I. Worldwide molecular epidemiology of HIV. Rev Saude Publica. 40(2):331-45, 2006.

Rits-Volloch, S.; Frey, G.; Harrison, S.C.; Chen, B. Restraining the conformation of HIV-1 gp120 by removing a flexible loop. Embo J. 2006;25:5026–5035.

Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McClutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. Science. 288:55-56.

Roux K.H., Taylor K.A.AIDS virus envelope spike structure Curr. Opin. Struct. Biol., 17 (2) (2007), pp. 244-252

Samson, M.; Libert, F.; Doranz, B.J.; Rucker, J.; Liesnard, C.; Farber, C.M.; Saragosti, S.; Lapoumeroulie, C.; Cognaux, J.; Forceille, C.; Muyldermans, G.; Verhofstede, C.; Burtorboy, G.; Georgers, M.; Imai, T.; Rana, S.; Smyth, R.J.; Collman, R.G.; Doms, R.W.; Vassart, G.; Parmentier, M. (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382 (1996), pp. 722-725.

Schaeffer, D.J.; Krylov, V.S. Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf. 2000;45(3):208–227.

Scarlatti, G.; E. Tresoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, H.K. Deng, M.S. Malnati, A. Plebani, A.G. Siccardi, D.R. Littman, E. Fenyo, P. Lusso. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med., 3 (1997), pp. 1259-1265.

Sethi, A. K., D. D. Celentano, S. J. Gange, R. D. Moore, and J. E. Gallant. 2003. Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance. Clin. Infect. Dis. 37:1112-1118.

Stone, V. E., J. Jordan, J. Tolson, R. Miller, and T. Pilon. 2004.Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral Therapy:

Self-Report of the Relative Importance of Multiple Attributes of Highly Active Antiretroviral Therapy (HAART) Regimens in Predicting Adherence. J. Acquir. Immune. Defic. Syndr. 36:808-816.

Singh, I.; Bharate, S.; Bhutani, K. Anti-HIV natural products. Current Sci. 2005; 89(2):269–290.

Temesgen, Z., D. Warnke, and M. J. Kasten. 2006. Current status of antiretroviral therapy. Expert. Opin. Pharmacother. 7:1541-1554.

Triques, K., A. Bourgeois, N. Vidal, E. Mpoudi-Ngole, C. Mulanga-Kabeya, N. Nzilambi, N. Torimiro, E. Saman, E. Delaporte, and M. Peeters.2000. Near-Full-Length Genome Sequencing of Divergent African HIV Type 1 Subtype F Viruses Leads to the Identification of a New HIV Type 1 Subtype Designated K. AIDS Res. Hum. Retroviruses.16:139-151.

Votteler, J.; Schubert, U. Human immunodeficiency viruses: molecular biology In: Mahy, B.J.W.; Van Regenmortel, M.H.V. Desk Encyclopedia of General Virology. Academic Press, San Diego, EUA, 2008, p. 474-481.

Walmsley, S. et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antirretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial.Journal of acquired immune deficiency síndromes (1999) 70.5(2015):515.

Wigg, M.D. Vírus da imunodeficiência humana. Introdução à Virologia Humana, ed. G. Koogan. Rio de Janeiro, 2002.

Yang, X., R. Wyatt, J. Sodroski. (2001). Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75:1165-1171.